BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
24.45 EUR
-0.1 (-0.41%)
BLC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 33 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of BLC while its profitability can be described as average. BLC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
BLC had a positive operating cash flow in the past year.
Of the past 5 years BLC 4 years were profitable.
In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.08%, BLC is doing worse than 75.76% of the companies in the same industry.
The Return On Equity of BLC (0.74%) is worse than 72.73% of its industry peers.
BLC has a better Return On Invested Capital (6.37%) than 60.61% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 6.56%.
The last Return On Invested Capital (6.37%) for BLC is above the 3 year average (6.13%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROIC | 6.37% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.22%
ROIC(3y)6.13%
ROIC(5y)5.72%
1.3 Margins
With a Profit Margin value of 0.11%, BLC is not doing good in the industry: 75.76% of the companies in the same industry are doing better.
BLC's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 8.14%, BLC is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
BLC's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 67.80%, BLC is in the better half of the industry, outperforming 75.76% of the companies in the same industry.
BLC's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.14% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.34%
OM growth 5Y0.66%
PM growth 3Y-66.7%
PM growth 5Y-48.68%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
BLC has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for BLC remains at a similar level compared to 5 years ago.
BLC has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.39, we must say that BLC is in the distress zone and has some risk of bankruptcy.
BLC's Altman-Z score of 1.39 is on the low side compared to the rest of the industry. BLC is outperformed by 69.70% of its industry peers.
The Debt to FCF ratio of BLC is 12.84, which is on the high side as it means it would take BLC, 12.84 years of fcf income to pay off all of its debts.
BLC has a Debt to FCF ratio (12.84) which is comparable to the rest of the industry.
A Debt/Equity ratio of 5.31 is on the high side and indicates that BLC has dependencies on debt financing.
BLC's Debt to Equity ratio of 5.31 is on the low side compared to the rest of the industry. BLC is outperformed by 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.31 | ||
| Debt/FCF | 12.84 | ||
| Altman-Z | 1.39 |
ROIC/WACC1.27
WACC5.01%
2.3 Liquidity
A Current Ratio of 1.39 indicates that BLC should not have too much problems paying its short term obligations.
The Current ratio of BLC (1.39) is better than 69.70% of its industry peers.
BLC has a Quick Ratio of 1.19. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
BLC has a Quick ratio of 1.19. This is in the better half of the industry: BLC outperforms 75.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.33% over the past year.
Measured over the past years, BLC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.37% on average per year.
The Revenue has been growing slightly by 6.35% in the past year.
Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
BLC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.18% yearly.
Based on estimates for the next years, BLC will show a small growth in Revenue. The Revenue will grow by 7.69% on average per year.
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 349.29 indicates a quite expensive valuation of BLC.
BLC's Price/Earnings ratio is a bit more expensive when compared to the industry. BLC is more expensive than 78.79% of the companies in the same industry.
BLC is valuated expensively when we compare the Price/Earnings ratio to 26.61, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 9.78, the valuation of BLC can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 84.85% of the companies listed in the same industry.
BLC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.01.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 349.29 | ||
| Fwd PE | 9.78 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BLC is valued cheaply inside the industry as 84.85% of the companies are valued more expensively.
BLC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BLC is cheaper than 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.63 | ||
| EV/EBITDA | 5.62 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)18.39
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y6.18%
5. Dividend
5.1 Amount
BLC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:BLC (12/22/2025, 7:00:00 PM)
24.45
-0.1 (-0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.78%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap180.20M
Revenue(TTM)491.18M
Net Income(TTM)530.00K
Analysts83.33
Price Target36.72 (50.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.55%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.5%
EPS NY rev (3m)-16.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 349.29 | ||
| Fwd PE | 9.78 | ||
| P/S | 0.37 | ||
| P/FCF | 5.63 | ||
| P/OCF | 1.96 | ||
| P/B | 2.5 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.62 |
EPS(TTM)0.07
EY0.29%
EPS(NY)2.5
Fwd EY10.22%
FCF(TTM)4.34
FCFY17.76%
OCF(TTM)12.48
OCFY51.06%
SpS66.65
BVpS9.77
TBVpS-16.27
PEG (NY)18.39
PEG (5Y)N/A
Graham Number3.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROCE | 8.67% | ||
| ROIC | 6.37% | ||
| ROICexc | 6.75% | ||
| ROICexgc | 12.06% | ||
| OM | 8.14% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.51% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.22%
ROIC(3y)6.13%
ROIC(5y)5.72%
ROICexc(3y)6.56%
ROICexc(5y)6.11%
ROICexgc(3y)13.97%
ROICexgc(5y)12.75%
ROCE(3y)8.35%
ROCE(5y)7.8%
ROICexgc growth 3Y2.87%
ROICexgc growth 5Y-0.99%
ROICexc growth 3Y7.59%
ROICexc growth 5Y0.26%
OM growth 3Y5.34%
OM growth 5Y0.66%
PM growth 3Y-66.7%
PM growth 5Y-48.68%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score7
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.31 | ||
| Debt/FCF | 12.84 | ||
| Debt/EBITDA | 3.78 | ||
| Cap/Depr | 98.36% | ||
| Cap/Sales | 12.22% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.12% | ||
| Profit Quality | 6037.74% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 1.39 |
F-Score7
WACC5.01%
ROIC/WACC1.27
Cap/Depr(3y)93.08%
Cap/Depr(5y)92.09%
Cap/Sales(3y)11.16%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
EBIT growth 1Y17.78%
EBIT growth 3Y7.03%
EBIT growth 5Y5.81%
EBIT Next Year137.78%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y1.88%
FCF growth 3Y107.42%
FCF growth 5Y33.53%
OCF growth 1Y13.78%
OCF growth 3Y17.4%
OCF growth 5Y14.22%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 349.29 and the Price/Book (PB) ratio is 2.5.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.55%.